Encompass Health Posts Strong Q3 Earnings, Revenue Jumps 9.4%

TL;DR

**EHC is crushing it with double-digit revenue and profit growth, making it a solid buy in the healthcare sector.**

AI Summary

Encompass Health Corp (EHC) reported a strong third quarter and nine-month period ending September 30, 2025, demonstrating significant growth in revenue and net income. For the three months ended September 30, 2025, net operating revenues increased by 9.4% to $1,477.5 million from $1,351.0 million in the prior year. Net income attributable to Encompass Health common shareholders rose by 16.9% to $126.5 million, up from $108.2 million in Q3 2024. Diluted EPS also saw a healthy increase, reaching $1.24 compared to $1.06 in Q3 2024. Over the nine-month period, net operating revenues grew 10.7% to $4,390.6 million from $3,968.2 million, and net income attributable to Encompass Health surged by 25.5% to $420.1 million from $334.8 million. The company's balance sheet shows a decrease in current portion of long-term debt to $39.0 million from $138.6 million at December 31, 2024, and an increase in total assets to $6,865.7 million from $6,534.7 million. Key risks include high concentration in Medicare reimbursement and potential impacts from staffing shortages and competitive pressures.

Why It Matters

Encompass Health's robust financial performance, with significant increases in revenue and net income, signals strong operational execution in a competitive healthcare landscape. For investors, this indicates healthy growth and potential for continued shareholder returns, evidenced by increased EPS and dividends. Employees benefit from a growing company, potentially leading to more stable employment and opportunities, though staffing shortages remain a risk. Customers can expect continued investment in healthcare services, while the broader market sees a key player in post-acute care demonstrating resilience amidst regulatory and economic uncertainties, including inflation and potential government shutdowns. The company's ability to navigate Medicare regulations and competitive pressures will be crucial for sustained success.

Risk Assessment

Risk Level: medium — The risk level is medium due to the company's high concentration in Medicare regulations and reimbursement, as explicitly stated in the cautionary statements. Reductions or delays in Medicare payments could significantly decrease revenues. Additionally, the filing highlights the inability to attract and retain nurses and therapists as a key challenge, which could increase staffing costs and adversely affect financial results, as it has in the past.

Analyst Insight

Investors should consider EHC's consistent growth in net operating revenues and net income, alongside its reduced current debt, as positive indicators. Monitor developments in Medicare reimbursement policies and the company's strategies for talent acquisition and retention, as these are critical for sustained performance. The dividend increase to $0.19 per share in Q3 2025 from $0.17 in Q3 2024 also suggests confidence in future cash flows.

Financial Highlights

revenue

$1,477.5M

total Assets

$6,865.7M

net Income

$126.5M

eps

$1.24

revenue Growth

+9.4%

Revenue Breakdown

Key Numbers

• $1.48B — Net Operating Revenues (Increased 9.4% from $1.35B in Q3 2024 to $1.48B in Q3 2025.)
• $126.5M — Net Income Attributable to Encompass Health (Increased 16.9% from $108.2M in Q3 2024 to $126.5M in Q3 2025.)
• $1.24 — Diluted EPS (Increased from $1.06 in Q3 2024 to $1.24 in Q3 2025.)
• $4.39B — Nine-Month Net Operating Revenues (Increased 10.7% from $3.97B in 2024 to $4.39B in 2025.)
• $420.1M — Nine-Month Net Income Attributable to Encompass Health (Increased 25.5% from $334.8M in 2024 to $420.1M in 2025.)
• $39.0M — Current Portion of Long-Term Debt (Decreased significantly from $138.6M at Dec 31, 2024, indicating improved liquidity.)
• $6.87B — Total Assets (Increased from $6.53B at Dec 31, 2024, reflecting growth in property and equipment.)
• 100.7M — Common Shares Outstanding (Slightly decreased from 100.8M at the beginning of the nine-month period, influenced by share repurchases.)
• $0.19 — Dividend Per Share (Declared for Q3 2025, up from $0.17 in Q3 2024.)
• $81.7M — Common Stock Repurchases (Amount spent on repurchases during the nine months ended September 30, 2025.)

Key Players & Entities

• Encompass Health Corp (company) — Registrant and primary entity in the filing
• Medicare (regulator) — Primary payor and regulatory body for EHC's services
• New York Stock Exchange (regulator) — Exchange where EHC Common Stock is registered
• $1,477.5 million (dollar_amount) — Net operating revenues for Q3 2025
• $1,351.0 million (dollar_amount) — Net operating revenues for Q3 2024
• $126.5 million (dollar_amount) — Net income attributable to Encompass Health for Q3 2025
• $108.2 million (dollar_amount) — Net income attributable to Encompass Health for Q3 2024
• $1.24 (dollar_amount) — Diluted EPS for Q3 2025
• $1.06 (dollar_amount) — Diluted EPS for Q3 2024
• $39.0 million (dollar_amount) — Current portion of long-term debt as of September 30, 2025

FAQ

Risk Factors

• Medicare Reimbursement Dependence [high — regulatory]: A significant portion of Encompass Health's revenue is derived from Medicare. Changes in Medicare reimbursement rates or policies could materially impact financial performance. For the nine months ended September 30, 2025, net operating revenues were $4,390.6 million, with a substantial portion tied to government payors.
• Staffing Shortages [high — operational]: The healthcare industry faces ongoing challenges with staffing shortages, particularly for skilled nurses and therapists. This can lead to increased labor costs and potential limitations on service capacity. Salaries and benefits represented $2,314.8 million of operating expenses for the nine months ended September 30, 2025.
• Competitive Pressures [medium — market]: The post-acute care market is competitive, with numerous providers vying for patients. Encompass Health faces competition from other inpatient rehabilitation facilities and home health agencies, which could affect market share and pricing power.
• Interest Rate Sensitivity [medium — financial]: The company has outstanding debt, and interest expense was $93.0 million for the nine months ended September 30, 2025. Rising interest rates could increase the cost of servicing this debt, impacting profitability.

Industry Context

Encompass Health operates in the post-acute care sector, which includes inpatient rehabilitation and home health services. This sector is characterized by increasing demand driven by an aging population and a shift towards value-based care. The industry faces significant regulatory oversight, particularly concerning reimbursement policies from government programs like Medicare.

Regulatory Implications

The company's heavy reliance on Medicare reimbursement (9.4% revenue growth in Q3 2025) makes it susceptible to changes in government healthcare policy. Potential shifts in reimbursement models or rate adjustments could significantly impact revenue and profitability. Compliance with healthcare regulations remains a critical operational focus.

What Investors Should Do

1. Monitor Medicare reimbursement policy changes.
2. Assess the company's ability to manage labor costs and staffing.
3. Evaluate the impact of share repurchases and dividend increases.
4. Analyze competitive positioning within the post-acute care market.

Key Dates

• 2025-09-30: End of Third Quarter and Nine-Month Period — Reported strong revenue growth of 9.4% for Q3 and 10.7% for the nine months, with net income increasing by 16.9% and 25.5% respectively, indicating robust operational performance.
• 2025-09-30: Declaration of Q3 Dividend — Dividend per share of $0.19 declared, an increase from $0.17 in Q3 2024, signaling confidence in future earnings and commitment to returning capital to shareholders.
• 2025-09-30: Completion of Share Repurchases — Spent $81.7 million on common stock repurchases during the nine-month period, demonstrating a strategy to enhance shareholder value by reducing share count.

Glossary

Net operating revenues

The total revenue generated from the company's primary business operations, excluding items like interest income or gains from asset sales. (Key indicator of top-line growth and business activity, showing a 9.4% increase to $1,477.5 million in Q3 2025.)

Diluted EPS

Earnings per share calculated after accounting for all potential dilutive securities, such as stock options and convertible bonds. (Provides a more conservative measure of profitability per share, increasing to $1.24 in Q3 2025 from $1.06 in Q3 2024.)

Noncontrolling interests

The portion of equity in a subsidiary that is not attributable to the parent company. (Reflects the share of net income belonging to external shareholders in consolidated subsidiaries, which was $48.1 million in Q3 2025.)

Equity in net income of nonconsolidated affiliates

The company's share of profits or losses from investments in companies where it does not have a controlling interest. (Indicates the performance of strategic partnerships or joint ventures, with a loss of $1.2 million in Q3 2025.)

Discontinued operations

Financial results of a business segment that the company has decided to sell or dispose of. (Shows the financial impact of divested operations, which resulted in a net loss of $0.4 million in Q3 2025.)

Year-Over-Year Comparison

Encompass Health demonstrated robust year-over-year performance. Net operating revenues for the third quarter of 2025 increased by 9.4% to $1,477.5 million, compared to $1,351.0 million in Q3 2024. Net income attributable to common shareholders saw a substantial rise of 16.9% to $126.5 million. Diluted EPS also improved to $1.24 from $1.06. The balance sheet shows a healthy decrease in the current portion of long-term debt to $39.0 million from $138.6 million at year-end 2024, alongside an increase in total assets to $6,865.7 million.

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share EHC New York Stock Exchange

Filing Documents

• ehc-20250930.htm (10-Q) — 1472KB
• ehc10q93025ex22.htm (EX-22) — 48KB
• ehc10q93025ex311.htm (EX-31.1) — 14KB
• ehc10q93025ex312.htm (EX-31.2) — 14KB
• ehc10q93025ex321.htm (EX-32.1) — 10KB
• ehc10q93025ex322.htm (EX-32.2) — 9KB
• 0000785161-25-000115.txt ( ) — 7247KB
• ehc-20250930.xsd (EX-101.SCH) — 41KB
• ehc-20250930_cal.xml (EX-101.CAL) — 95KB
• ehc-20250930_def.xml (EX-101.DEF) — 176KB
• ehc-20250930_lab.xml (EX-101.LAB) — 566KB
• ehc-20250930_pre.xml (EX-101.PRE) — 420KB
• ehc-20250930_htm.xml (XML) — 998KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 4.

Controls and Procedures

Controls and Procedures 34 PART II Other Information Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Risk Factors

Risk Factors 35 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 36 Item 5. Other Information 36 Item 6. Exhibits 37 NOTE TO READERS As used in this report, the terms "Encompass Health," "we," "us," "our," and the "Company" refer to Encompass Health Corporation and its consolidated subsidiaries, unless otherwise stated or indicated by context. This drafting style is suggested by the Securities and Exchange Commission and is not meant to imply that Encompass Health Corporation, the publicly traded parent company, owns or operates any specific asset, business, or property. The hospitals, operations, and businesses described in this filing are primarily owned and operated by subsidiaries of the parent company. In addition, we use the term "Encompass Health Corporation" to refer to Encompass Health Corporation alone wherever a distinction between Encompass Health Corporation and its subsidiaries is required or aids in the understanding of this filing. i CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This quarterly report contains historical information, as well as forward-looking statements that involve known and unknown risks and relate to, among other things, future events, changes to Medicare reimbursement and other healthcare laws and regulations from time to time, our business strategy, labor cost trends, our dividend and stock repurchase strategies, our financial plans, our growth plans, our future financial performance, our projected business results, or our projected capital expenditures. In some cases, the reader can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "targets," "potential," or "continue" or the negative of these terms or other comparable terminology. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertaintie

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) Encompass Health Corporation and Subsidiaries Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 (In Millions, Except Per Share Data) Net operating revenues $ 1,477.5 $ 1,351.0 $ 4,390.6 $ 3,968.2 Operating expenses: Salaries and benefits 784.8 732.1 2,314.8 2,144.2 Other operating expenses 231.1 202.4 662.4 596.2 Occupancy costs 14.9 14.4 44.5 42.6 Supplies 64.6 60.6 189.9 176.7 General and administrative expenses 56.1 54.0 167.8 154.7 Depreciation and amortization 82.4 78.4 241.5 221.6 Total operating expenses 1,233.9 1,141.9 3,620.9 3,336.0 Loss on early extinguishment of debt — 0.4 — 0.4 Interest expense and amortization of debt discounts and fees 30.8 34.9 93.0 104.4 Other income ( 5.9 ) ( 9.3 ) ( 15.1 ) ( 18.0 ) Equity in net income of nonconsolidated affiliates ( 1.2 ) ( 0.7 ) ( 3.5 ) ( 2.8 ) Income from continuing operations before income tax expense 219.9 183.8 695.3 548.2 Provision for income tax expense 44.9 36.0 137.5 112.6 Income from continuing operations 175.0 147.8 557.8 435.6 Loss from discontinued operations, net of tax ( 0.4 ) ( 0.7 ) ( 1.8 ) ( 3.2 ) Net income 174.6 147.1 556.0 432.4 Less: Net income attributable to noncontrolling interests ( 48.1 ) ( 38.9 ) ( 135.9 ) ( 97.6 ) Net income attributable to Encompass Health $ 126.5 $ 108.2 $ 420.1 $ 334.8 Weighted average common shares outstanding: Basic 100.5 99.9 100.5 99.9 Diluted 102.3 102.1 102.3 102.2 Earnings per common share: Basic earnings per share attributable to Encompass Health common shareholders: Continuing operations $ 1.26 $ 1.09 $ 4.19 $ 3.36 Discontinued operations — ( 0.01 ) ( 0.02 ) ( 0.03 ) Net income $ 1.26 $ 1.08 $ 4.17 $ 3.33 Diluted earnings per share attributable to Encompass Health common shareholders: Continuing operations $ 1.24 $ 1.07 $ 4.13 $ 3.31 Discontinued operations — ( 0.01 ) ( 0.02

View Full Filing

View this 10-Q filing on SEC EDGAR